Long Term Results and Complications After Epistaxis Treatment

December 1, 2015 updated by: University of Zurich

Langzeitresultate Und Komplikationen Nach Einer Epistaxisbehandlung

The aim of this study is to find the most agreeable and in the long term most efficient treatment for epistaxis.

Study Overview

Status

Completed

Conditions

Detailed Description

In the general population epistaxis occurs quite frequently. Approximately 60% of persons will be affected once in their lifetime, and 6% thereof will seek medical advice. Thereby anterior and posterior epistaxis are discerned. Anterior epistaxis is usually located at the Locus Kisselbachii, while posterior bleeds are found further back in the nose. There, most bleeds will originate from the A. sphenopalatina or the A. ethmoidalis.

Different treatment modalities exist. Anterior epistaxis are usually easier to treat than posterior ones. The aim of this study is to find the most efficient treatment. This involves the assessment of long term results and potential sequelae. Existing data will be complemented with information about recurrences and complications. The question is: Which treatment method leads to the least numbers of recurrences in the long term with the fewest long term sequelae?

Secondly, the most agreeable, least painful treatment method is to be identified. Therefore we will send out questionnaires to patients that were treated between March 29, 2007 and April 1st, 2008 at the Zurich University Hospital.

Study Type

Observational

Enrollment (Actual)

591

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
      • Zurich, Switzerland, 8091
        • Zurich University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 80 years (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients treated between March 29, 2007 and April 1st, 2008 for epistaxis at the ENT Dept. of the Zurich University Hospital

Description

Inclusion Criteria:

All patients treated during the study period with known address and who did not decease in the meantime.

Exclusion Criteria:

Insufficiently filled out questionnaires; Obvious lack of ability to remember (as tested by control questions); Known mental disability

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Electric coagulation
Patients with anterior epistaxis, treated with electric coagulation
Chemical coagulation
Patients with anterior epistaxis, treated with chemical coagulation
Outpatient tamponade
Patients with posterior epistaxis, treated with tamponade as an outpatient
Inpatient tamponade
Patients with posterior epistaxis, treated with tamponade and kept in the hospital.
Surgery
Patients with posterior epistaxis, treated with surgery as inpatients
Foley balloon catheter
Patients with posterior epistaxis, treated as inpatients with Foley balloon catheter
Combined treatment
Patients with posterior epistaxis, treated as inpatients with a combination of methods

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of patients without recurrence
Time Frame: Up to 8 years post-treatment
Up to 8 years post-treatment

Secondary Outcome Measures

Outcome Measure
Time Frame
Discomfort caused by treatment
Time Frame: Up to 1 day post-treatment
Up to 1 day post-treatment

Other Outcome Measures

Outcome Measure
Time Frame
Number of complications due to treatment
Time Frame: Up to 8 years post-treatment
Up to 8 years post-treatment
Sequelae due to treatment
Time Frame: Up to 8 years post-treatment
Up to 8 years post-treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Zurich

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2014

Primary Completion (ACTUAL)

December 1, 2015

Study Completion (ACTUAL)

December 1, 2015

Study Registration Dates

First Submitted

April 28, 2014

First Submitted That Met QC Criteria

April 29, 2014

First Posted (ESTIMATE)

April 30, 2014

Study Record Updates

Last Update Posted (ESTIMATE)

December 2, 2015

Last Update Submitted That Met QC Criteria

December 1, 2015

Last Verified

December 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SM_21_01_2014
  • KEK-ZH-Nr: 2013-0519 (OTHER: Zurich Ethics Committee)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nosebleed (Epistaxis) - Posterior or Anterior

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe